Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2806120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Feng Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, 200041 Shanghai, China. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Pudong New Area Science and Technology Development Fund for people’s livelihood in public institutions.
Abstract (Originalsprache)
Background
N6-methyladenosine (m6A) RNA methylation regulators have been implicated in the carcinogenesis and progress of a variety of cancers. Until now, the effects of them on intrahepatic cholangiocarcinoma (ICC) have been poorly understood.
Methods
We used the GEO databases to systematically evaluate the expression profiles of 36 m6A RNA methylation regulators in ICC patients and produced a signature to assess its prognostic values. In vitro experiments were implemented to confirm the expression level.
Results
Compared to normal intrahepatic bile duct tissues, more than half of these 36 genes showed different levels of expression in ICC tissues. Two groups emerged from the consensus cluster analysis of these 36 genes. The two cluster of patients had significantly different clinical outcomes. In addition, we created a m6A-related prognostic signature that performed exceptionally well in the prognostic categorization of ICC patients, based on the ROC curves, Kaplan-Meier curves, and univariate and multivariate Cox regression analyses. Further research showed that there was a significant association between the m6A-related signature and the manifestations of tumor immune microenvironment in ICC. The expression level and biological effect of METTL16, one of the two m6A RNA methylation regulators incorporated in the signature, were confirmed and explored by using in vitro experiments.
Conclusions
This analysis revealed the predictive roles of m6A RNA methylation regulators in ICC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, 200041 Shanghai, China.
- Department of Hepatobiliary Surgery, Changzheng Hospital, Second Military Medical University, 200041 Shanghai, China.
- Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, 200041 Shanghai, China.
- Digestive Disease Center, The Second People's Hospital of Jiulongpo District, 401324 Chongqing, China.
- Department of Gastroenterology, Punan Branch of Renji Hospital, Shanghai Jiaotong University School of Medicine, 200125 Shanghai, China.
- Department of Gastroenterology, Shanghai Punan Hospital of Pudong New District, 200125 Shanghai, China.
Förderung
- Shanghai Pudong New Area Science and Technology Development Fund for people’s livelihood in public institutions
Zitieren
APA
Wei, F., Zhang, J. N., Zhao, Y. Q., Lyu, H., & Chen, F. (2023). Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2806120
Vancouver
Wei F, Zhang JN, Zhao YQ, Lyu H, Chen F. Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2806120
BibTeX
@article{Wei2023,
author = {Wei, Feng and Zhang, Jia-Ning and Zhao, Yu-Qing and Lyu, Hongwei and Chen, Fengyuan},
title = {Expression of m6A RNA Methylation Regulators and Their Clinical Predictive Value in Intrahepatic Cholangiocarcinoma},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2806120}
}
EUVIMED